These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 2546775)
21. Evolution of antifungal agents: past, present, and future. Drouhet E; Dupont B Rev Infect Dis; 1987; 9 Suppl 1():S4-14. PubMed ID: 3544144 [TBL] [Abstract][Full Text] [Related]
22. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Lyman CA; Walsh TJ Drugs; 1992 Jul; 44(1):9-35. PubMed ID: 1379913 [TBL] [Abstract][Full Text] [Related]
23. Antifungal treatment in pediatric patients. Zaoutis TE; Benjamin DK; Steinbach WJ Drug Resist Updat; 2005 Aug; 8(4):235-45. PubMed ID: 16054422 [TBL] [Abstract][Full Text] [Related]
24. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. Van Cutsem J Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313 [TBL] [Abstract][Full Text] [Related]
25. Antifungal agents in children. Steinbach WJ Pediatr Clin North Am; 2005 Jun; 52(3):895-915, viii. PubMed ID: 15925667 [TBL] [Abstract][Full Text] [Related]
26. Current and emerging azole antifungal agents. Sheehan DJ; Hitchcock CA; Sibley CM Clin Microbiol Rev; 1999 Jan; 12(1):40-79. PubMed ID: 9880474 [TBL] [Abstract][Full Text] [Related]
28. New antifungal drugs and new clinical trials: interpreting results may be difficult. Girmenia C; Martino P Curr Opin Oncol; 2003 Jul; 15(4):283-8. PubMed ID: 12874505 [TBL] [Abstract][Full Text] [Related]
29. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Fera MT; La Camera E; De Sarro A Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707 [TBL] [Abstract][Full Text] [Related]
30. [Importance of the new triazoles in antifungal therapy]. Durmaz B Mikrobiyol Bul; 1991 Jan; 25(1):118-23. PubMed ID: 1652677 [TBL] [Abstract][Full Text] [Related]
31. Testing of organisms for susceptibility to triazoles: is it justified? Kobayashi GS; Spitzer ED Eur J Clin Microbiol Infect Dis; 1989 May; 8(5):387-9. PubMed ID: 2546774 [No Abstract] [Full Text] [Related]
32. New approaches to antifungal chemotherapy. Viviani MA; de Marie S; Graybill JR; Yamaguchi H; Anaissie E; Caillot D Med Mycol; 1998; 36 Suppl 1():194-206. PubMed ID: 9988508 [TBL] [Abstract][Full Text] [Related]
33. Changing strategies for the management of invasive fungal infections. Rapp RP Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487 [TBL] [Abstract][Full Text] [Related]
35. Fundamental Concepts of Azole Compounds and Triazole Antifungals: A Beginner's Review. Martínez-Matías N; Rodríguez-Medina JR P R Health Sci J; 2018 Sep; 37(3):135-142. PubMed ID: 30188556 [TBL] [Abstract][Full Text] [Related]
36. Current status and future of antifungal therapy for systemic mycoses. Nosanchuk JD Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):75-84. PubMed ID: 18221136 [TBL] [Abstract][Full Text] [Related]
37. Combination therapy for systemic mycosis. Polak A Infection; 1989; 17(4):203-9. PubMed ID: 2548963 [No Abstract] [Full Text] [Related]
38. New investigational antifungal agents for treating invasive fungal infections. Hossain MA; Ghannoum MA Expert Opin Investig Drugs; 2000 Aug; 9(8):1797-813. PubMed ID: 11060778 [TBL] [Abstract][Full Text] [Related]
39. A new era of antifungal therapy. Wingard JR; Leather H Biol Blood Marrow Transplant; 2004 Feb; 10(2):73-90. PubMed ID: 14750074 [TBL] [Abstract][Full Text] [Related]
40. Recent approaches to antifungal therapy for invasive mycoses. Mathew BP; Nath M ChemMedChem; 2009 Mar; 4(3):310-23. PubMed ID: 19170067 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]